Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study.
OBJECTIVE
The aim of this study was to assess the effects of nasal salmon calcitonin (SCT) administration on bone turnover in ovariectomized women.


METHODS
Patients who had undergone bilateral ovariectomy 7 days previously, received either calcium supplementation (1000 mg/day, together with nasal SCT (100 IU/day) (n = 19) or the same calcium supplementation together with a placebo intranasal spray daily (n = 19), for 2 years.


RESULTS
In the calcium-only-treated subjects, lumbar bone mineral density (BMD) was found to have decreased significantly (P < 0.001), 6 months after surgery and remained at this level until the end of the study. In the SCT-treated group, BMD remained stable during the 1st year and then decreased gradually, reaching a statistically significant level in the 2nd year. Mean serum osteocalcin concentration was unchanged during the 1st year of SCT treatment but was significantly elevated during the 2nd year (P < 0.01). The observed rise in serum osteocalcin concentration and urinary hydroxyproline excretion during the 2nd year of treatment with SCT was accompanied by a significant rise in serum calcitonin levels (P < 0.001 after 18 months and P < 0.01 after 24 months).


CONCLUSIONS
This study shows that continuous treatment with intranasal SCT is able to prevent the bone loss that follows ovariectomy.
Grigoriou
O
O
2nd Department of Obstetrics and Gynecology, University of Athens, Areteion Hospital, Greece.
Papoulias
I
I
Vitoratos
N
N
Papadias
C
C
Konidaris
S
S
Antoniou
G
G
Chryssikopoulos
A
A
D000281:Administration, Intranasal; D000328:Adult; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology*; D002118:Calcium / Q000652:urine; D015331:Cohort Studies; D003404:Creatinine / Q000652:urine; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010052:Ovariectomy; D017698:Postmenopause / Q000187:drug effects* / Q000502:physiology
D000700:Analgesics; D015675:Osteocalcin; C028815:salmon calcitonin; D002116:Calcitonin; D003404:Creatinine; D006909:Hydroxyproline; D002118:Calcium